AntithrombinemiaEPPATHUSNCT07276074
Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
An observational study of Antithrombinemia, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially low-molecular-weight heparin (LMWH). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Antithrombinemia
- How many people
- 160 participants
- Where
- 1 siteFrance
- Study dates
- 18 Dec 2024to 31 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: - Adult subject (≥18 years old) having received antithrombin during the study period, in intensive care or operating room during the period from January 1, 2022 to December 31, 2023.
Who may be able to join
- Adult subject (≥18 years old)
- Female and male
- Having received antithrombin during the study period, in intensive care or operating room during the period from January 1, 2022 to December 31, 2023.
Who cannot join
- Subject (and/or their legal representative, if applicable) having expressed their opposition to the reuse of their data for scientific research purposes
- Minor subject
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service d'Anesthésie et Réanimation chirurgicale - CHU de Strasbourg - France
Strasbourg
Xavier DELABRANCHE, MD, 33 3 69 55 09 36, xavier.delabranche@chru-strasbourg.fr
Xavier DELABRANCHE, MD
About this study
Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially low-molecular-weight heparin (LMWH).
In intensive care, patients are mostly treated with anticoagulants for either preventive or curative purposes, particularly for those whose care requires renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), or cardiopulmonary bypass (CPB). The use of various types of membranes associated with these procedures can lead to degradation of blood proteins (including AT). An imbalance in hemostasis can then occur, resulting in ineffective anticoagulation. At the Strasbourg University Hospitals (HUS), these medications are directly available in the intensive care units, allowing for immediate administration in an emergency. Pharmaceutical and medical analysis is therefore not performed before administration.
- Conditions
- Antithrombinemia
- Keywords
- Anticoagulants, Antithrombinemia, Extracorporeal membrane oxygenation, Renal replacement therapy, Cardiopulmonary bypass
What is being measured
The primary outcome is the main question the study is designed to answer.
Overview of antithrombin prescriptions
This is a retrospective study describing antithrombin prescriptions at the Strasbourg University Hospitals over a one-year period (from January 1, 2022 to December 31, 2023)
Measured: Up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2025
- Study start18 Dec 2024
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AntithrombinemiaStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07276074
- Sponsor's protocol ID
- 9308
- Acronym
- EPPATHUS
- Status last verified
- Mar 2025
- First submitted
- 28 Mar 2025
- Last updated
- 10 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
- ClinicalTrials.gov ID
- NCT07276074
- Acronym / sponsor ID
- EPPATHUS / 9308
- Conditions
- Antithrombinemia
- Keywords
- Anticoagulants, Antithrombinemia, Extracorporeal membrane oxygenation, Renal replacement therapy, Cardiopulmonary bypass
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 160 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 18 Dec 2024 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 10 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially low-molecular-weight heparin (LMWH).
In intensive care, patients are mostly treated with anticoagulants for either preventive or curative purposes, particularly for those whose care requires renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), or cardiopulmonary bypass (CPB). The use of various types of membranes associated with these procedures can lead to degradation of blood proteins (including AT). An imbalance in hemostasis can then occur, resulting in ineffective anticoagulation. At the Strasbourg University Hospitals (HUS), these medications are directly available in the intensive care units, allowing for immediate administration in an emergency. Pharmaceutical and medical analysis is therefore not performed before administration.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- - Adult subject (≥18 years old) having received antithrombin during the study period, in intensive care or operating room during the period from January 1, 2022 to December 31, 2023.
Key inclusion criteria (3 listed)
- Adult subject (≥18 years old)
- Female and male
- Having received antithrombin during the study period, in intensive care or operating room during the period from January 1, 2022 to December 31, 2023.
Key exclusion criteria (2 listed)
- Subject (and/or their legal representative, if applicable) having expressed their opposition to the reuse of their data for scientific research purposes
- Minor subject
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overview of antithrombin prescriptions
Time frame: Up to 1 year
This is a retrospective study describing antithrombin prescriptions at the Strasbourg University Hospitals over a one-year period (from January 1, 2022 to December 31, 2023)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Dec 2025.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Antithrombinemia, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xavier DELABRANCHE, MD (33 3 69 55 09 36, xavier.delabranche@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overview of antithrombin prescriptions (time frame: Up to 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2025.